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Abstract
Background: Prostate cancer is a leading cause of male cancer specific mortality. When cure by
radical prostatectomy is not possible the next line of prostate cancer treatment is androgen
deprivation. However prolonged androgen deprivation often results in relapse and androgen-
independent prostate cancer that is inevitably fatal despite optimal chemotherapy. The Hedgehog
signalling pathway has recently been implicated in prostate cancer development and metastasis.
EGFR or ErbB2 expression has been also correlated with androgen independence, shorter survival
and metastasis.
Results: We determined that the Hedgehog and ErbB signalling pathways are active in circulating
tumour cells isolated from androgen-independent prostate cancer patients and in the androgen-
independent prostate cancer cell line LNCaP C4-2B. As a basis for synergistic chemotherapy
protocols combinations of the Hedgehog specific inhibitor cyclopamine and the ErbB signalling
inhibitors gefitinib or lapatinib were tested in this study. Androgen-independent prostate cancer
cell growth was inhibited by a SMO inhibitor (cyclopamine) which blocks Hedgehog signalling and
by ErbB inhibitors (gefitinib and lapatinib). The isobologram and combination index method of
Chou and Talalay was used to evaluate drug interactions. Synergistic antiproliferation effects were
observed when the Hedgehog and ErbB inhibitors were combined.
Conclusion: Androgen-independent prostate cancer cell proliferation was associated with activity
of the Hedgehog and ErbB signalling pathways. Cyclopamine, gefitinib or lapatinib treatment
significantly decreased the proliferation of androgen-independent prostate cancer cells. The
Hedgehog pathway therefore represents a promising new therapeutic target in androgen-
independent prostate cancer. Synergistic effects were observed when Hedgehog and ErbB
inhibitors were used together. This study may have clinical implications for improving the treatment
of advanced prostate cancer.
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Background
Prostate cancer is a leading cause of male cancer related
deaths [1] and autopsy series have also found prostate car-
cinomas in the majority of men aged 60 to 70 years [2].
The incidence of prostate cancer diagnosis is also increas-
ing as awareness improves, PSA measurement is per-
formed more frequently and life expectancy increases [1].
Testicular factors were first linked to prostatic growth by
John Hunter in 1786, although the endocrine nature of
the relationship was not appreciated. Castration was sub-
sequently shown by Charles Huggins in the 1940s to
result in shrinkage of prostate cancer metastasis. Decreas-
ing circulating testosterone with androgen deprivation
therapy is currently used to treat metastatic prostate cancer
and those cancers that are not suitable for attempts at cure
with radiotherapy or surgery. This effectively shrinks
androgen-dependent tumours, both in the prostate and at
distant sites. However many men ultimately fail this ther-
apy and continuous androgen deprivation usually leads to
recurrent androgen-independent prostate cancer
(AIPC)[3]. Once AIPC develops the median survival with
the most effective therapeutic regimes is 20–24 months
[4,5]. The high mortality rate associated with prostate can-
cer is therefore linked to the development of AIPC and the
current lack of effective therapies. Developing new thera-
peutic approaches that target AIPC therefore has consider-
able potential for improving quality of life and survival of
patients with advanced prostate cancer.
AIPC that arises as a consequence of androgen deprivation
therapy may be due to increased activity of the androgen
receptor (AR) or cell signalling pathways [6]. Growth fac-
tor signalling has been linked to ligand independent activ-
ity of the AR [6]. The ErbB receptor family are
transmembranous receptors including EGFR, ErbB2,
ErbB3 and ErbB4 which have intracellular tyrosine kinase
domains. EGFR or ErbB2 expression has been correlated
with androgen independence, shorter survival and metas-
tasis [6-9]. Specific inhibitors of ErbB tyrosine kinase
receptors have been developed. Gefitinib (Astra-Zeneca)
is an EGFR receptor antagonist and lapatinib (Glaxo-
Smithkline) has kinase inhibitor activity, inhibiting EGFR
and ErbB2 activity. However their results in advanced
prostate cancer trials to date have not been promising
with the authors of one trial concluding that "gefitinib has
minimal single-agent activity in AIPC" [10].
The Hedgehog pathway has also recently been implicated
in prostate cancer development and metastasis [11].
Patched (PTCH) is the receptor for Hedgehog ligands
(Sonic, Indian and Desert), which in the absence of
Hedgehog inhibits Smoothened (SMO), a G protein cou-
pled-like receptor. When Hedgehog binds to PTCH, SMO
is disinhibited and initiates a signalling cascade that
results in activation of GLI transcription factors and
increased expression of target genes (including PTCH and
GLI1). Inhibition of the Hedgehog pathway induces
apoptosis and decreases invasiveness of prostate cancer
cells [11]. Recent studies have shown a high prevalence of
Hedgehog activity in high grade or metastatic prostate
cancers [11,12], but the contribution of Hedgehog signal-
ling to AIPC is unclear.
To clarify the role of ErbB and Hedgehog signalling in
AIPC we determined that these pathways are active in
both circulating tumour cells (CTC) isolated from
patients with androgen-independent prostate cancer and
in the androgen-independent prostate cancer cell line
LNCaP C4-2B. The specific hedgehog pathway inhibitor
cyclopamine and the ErbB pathway inhibitors gefitinib or
lapatinib significantly decreased the proliferation of
androgen-independent prostate cancer cells. A synergistic
effect of Hedgehog and ErbB inhibitors on prostate cancer
cell growth was also observed, consistent with both
Hedgehog and ErbB signalling contributing to the prolif-
eration of androgen-independent prostate cancer cells.
The Hedgehog pathway therefore represents a promising
new therapeutic target in androgen-independent prostate
cancer.
Results and discussion
To investigate the contribution of Hedgehog and ErbB
pathways to AIPC we analysed the androgen-independent
prostate cancer cell line LNCaP C4-2B and isolated CTC
from fifteen patients with advanced prostate cancer who
are on second line treatment having failed primary hor-
mone therapy (with a rising PSA in the face of castrate
serum testosterone levels) and are therefore androgen-
independent, (clinical characteristics: age 53–89 years,
median 76; last PSA 12–667 ng/ml, median 64; testoster-
one less than 0.7 nmol/L and duration of hormone ther-
apy 1.2–13.9 years, median 4.4). The use of CTC is
advantageous as biopsies are rarely performed on patients
at this cancer stage and obtaining CTC is a low risk mini-
mally invasive technique compared to biopsy. Immun-
ofluorescence analysis showed that each prostate cancer
patient sample contained more than 5 nucleated, EpCAM
positive CTC, which has been associated with a poor prog-
nosis in breast and prostate cancer [13,14]. No CTC were
observed in the normal controls. CTC expressed PTCH,
EGFR and ErbB2 protein (Figure 1A) and RNA (Figure
1B). A high background level of EGFR RNA expression
was detected in the control samples enriched from healthy
normal subjects. This expression of EGFR RNA by leuko-
cytes carried over during the the CTC enrichment proce-
dure was higher than previously reported [15]. In contrast,
we observed very good discrimination between the nor-
mal subjects and the androgen-independent patient
groups for ErbB2 (p  < 0.005), PTCH (p  < 0.005) and
DD3PCA3  (a prostate cancer specific RNA transcriptCancer Cell International 2008, 8:3 http://www.cancerci.com/content/8/1/3
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Circulating tumour cells isolated from AIPC patients are EpCAM, PTCH, ErbB2 and EGFR positive Figure 1
Circulating tumour cells isolated from AIPC patients are EpCAM, PTCH, ErbB2 and EGFR positive. (A) 
EpCAM, PTCH, ErbB2 and EGFR immunofluorescence in circulating tumour cells isolated from AIPC patients. (B) Relative 
PTCH, EGFR, ErbB2 and DD3PCA3 RNA expression in circulating tumour cells isolated from normal subjects and androgen-
independent prostate cancer patients.Cancer Cell International 2008, 8:3 http://www.cancerci.com/content/8/1/3
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DD3PCA3;  p  < 0.001) (Figure 1B), consistent with the
Hedgehog and ErbB pathways contributing to AIPC.
As we have been unable to establish proliferating cultures
of CTC for inhibitor and biochemical studies (Shaw and
Prowse, unpublished), to further investigate the role of
the Hedgehog and ErbB pathways in AIPC we have used
the androgen-independent prostate cancer cell line
LNCaP C4-2B. These cells were originally isolated and
characterised following growth in castrated athymic mice
of androgen-dependent LNCaP prostate cancer cells [16]
from the site of bony metastasis (LNCaP C4-2B)[17].
Importantly, the growth of LNCaP C4-2B cells is not
affected by withdrawal of androgens, confirming the
androgen independence of these cells and these cells
express androgen receptor and PSA (Figure 2) [17]. Hall-
marks of the majority of prostate cancers in vivo [18,19]
and characteristics not shared with other established pros-
tate cancer cell lines such as PC3 and DU145 [16]. In addi-
tion, LNCaP C4-2B cells express a promiscuous form of
the androgen receptor, having the most AR common sub-
stitution (T877A), which is repeatedly found in prostate
cancer tissue specimens of patients with AIPC [20]. Like
the CTCs, LNCaP C4-2B cells also express PTCH, EGFR
and ErbB2 RNA (Figure 2).
To determine the importance of the Hedgehog and ErbB
pathways to AIPC cell growth we treated LNCaP C4-2B
cells with specific inhibitors to cyclopamine (SMO inhib-
itor) which blocks Hedgehog signalling, gefitinib (EGFR
inhibitor) and lapatinib (EGFR and ErbB2 inhibitors),
either singularly or in combination. The growth of LNCaP
C4-2B cells in androgen free medium was significantly
reduced by treatment with the Hedgehog pathway inhibi-
tor cyclopamine, the EGFR inhibitor gefitinib and the
EGFR and ErbB2 inhibitor lapatinib. The effects were dose
dependent. Using cyclopamine between 0.0014–1 mM,
gefitinib at 0.017–10 µM and lapatinib at 0.01–10 µM
there was minimal affect at the lowest dose for each inhib-
itor and significantly greater inhibition at higher concen-
trations (Figure 3). Calculation of the drug concentration
(IC50) producing the median effect of 50% growth inhibi-
tion on the LNCaP C4-2B cell line in androgen free
medium was performed from the dose response curves for
each drug (cyclopamine 14 µM; gefitinib 168 nM; lapat-
inib 102 nM; Figure 3), and were similar to those reported
in the literature [21-23]. The PTCH receptor and GLI1
transcription factor are both constituents of the hedgehog
pathway which are also regulated by Hedgehog signalling.
Application of 14 µM cyclopamine for 24 hours to andro-
gen-independent LNCaP C4-2B cells resulted in decreased
expression of PTCH and GLI1 (Figure 4A), consistent with
cyclopamine inhibiting SMO and Hedgehog signalling
activity. The ErbB inhibitors gefitinib (168 nM) and lapat-
inib (102 nM) also inhibited EGF induced autophophor-
ylation of the EGFR in LNCaP C4-2B cells (Figure 4B–C).
Expression of PTCH, GLI1, ErbB2, EGFR, PSA and AR RNA in LNCaP C4-2B cells Figure 2
Expression of PTCH, GLI1, ErbB2, EGFR, PSA and AR RNA in LNCaP C4-2B cells.Cancer Cell International 2008, 8:3 http://www.cancerci.com/content/8/1/3
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In order to establish whether the combined effects of
Hedgehog and ErbB inhibitors were synergistic the isobo-
logram and combination index (CI) was calculated
according to the Chou and Talalay median effect principal
[24]. Inhibitors were applied to androgen-independent
LNCaP C4-2B cells at concentrations relative to their
respective IC50 values keeping the ratio of one drug to the
other constant. For each drug combination the MTT assays
were carried out in three separate experiments and the rel-
ative growth rates calculated in comparison with LNCaP
C4-2B cells cultured in androgen free medium in the
absence of any cytotoxic drugs. The Hedgehog inhibitor
Effect of (A) cyclopamine, (B) gefitinib and (C) lapatinib on  growth of androgen-independent prostate cancer cells Figure 3
Effect of (A) cyclopamine, (B) gefitinib and (C) lapat-
inib on growth of androgen-independent prostate 
cancer cells.
(A) Cyclopamine inhibits expression of PTCH and GLI1 RNA  in LNCaP C4-2B cells: control cells (lanes 1 and 3); 24 hrs 14  nM cyclopamine treatment (lanes 2 and 4) Figure 4
(A) Cyclopamine inhibits expression of PTCH and 
GLI1 RNA in LNCaP C4-2B cells: control cells (lanes 
1 and 3); 24 hrs 14 nM cyclopamine treatment (lanes 
2 and 4). Relative expression determined by QPCR (error 
bars show standard deviation). (B) Immunoblot showing 
inhibitory effect of 168 nM gefitinib on EGFR phosphoryla-
tion following EGF treatment in AIPC cells (lane 1: control; 
lane 2: 24 hr gefitinib; lane 3: 48 hr gefitinib). (C) Immunoblot 
showing inhibitory effect of 102 nM lapatinib on EGFR phos-
phorylation following EGF treatment in AIPC cells (lane 1: 
control; lane 2: 24 hr lapatinib; lane 3: 48 hr lapatinib).Cancer Cell International 2008, 8:3 http://www.cancerci.com/content/8/1/3
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Concentration effect curves of (A) single agent cyclopamine and gefitinib and their combinations, (B) single agent cyclopamine  and lapatinib and their combinations Figure 5
Concentration effect curves of (A) single agent cyclopamine and gefitinib and their combinations, (B) single 
agent cyclopamine and lapatinib and their combinations.Cancer Cell International 2008, 8:3 http://www.cancerci.com/content/8/1/3
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cyclopamine as single agent or in combination with the
ErbB inhibitors gefitinib or lapatinib inhibited the growth
of LNCaP C4-2B cells. Figure 5A shows the dose response
curve for cyclopamine and gefitinib applied alone and in
combination and Figure 5B shows the dose response
curve for cyclopamine and lapatinib applied alone and in
combination. Figure 6 shows the combination effect plots
and isobolograms for the inhibitor combinations. Table 1
shows the combination index for treating androgen-inde-
pendent LNCaP C4-2B cells with inhibitor combinations,
with values below 0.9 indicating synergism and above 1.1
antagonism. Strong synergistic effects resulted from the
combination of cyclopamine with gefitinib or lapatinib.
This is consistent with the antiproliferative results recently
reported following treatment with cyclopamine or gefit-
inib of androgen dependent LNCaP-C33 cells, the sponta-
neously arising androgen-independent LNCaP subline
C81 and androgen independent DU145 and PC3 cells
[21,25]. Importantly, combined cyclopamine and gefit-
inib treatment was also found to cause a high rate of inhi-
bition of proliferation [21] and a significant increase in
apoptotic death of androgen-independent LNCaP-C81,
DU145 and PC3 cells, although androgen dependent
LNCaP-C33 cells were less responsive to these agents [21].
Our CTC analysis is also consistent with reports that spec-
imens from advanced prostate cancer have higher levels of
SHH, PTCH-1 and GLI-1 as compared to samples from
localized PC and normal tissues or benign PrE cells
[11,21,26].
The synergy between cyclopamine and gefitinib or lapat-
inib may occur because of interactions between the
Hedgehog and ErbB pathways, consistent with EGF sig-
nalling selectively enhancing Hedgehog activity [27] and
cyclopamine treatment of PC3 cells causing downregula-
tion of EGFR expression [21]. Gefitinib has also been
reported to inhibit the activity of the androgen receptor,
enhancing its anti-proliferative affect [28]. Hedgehog and
ErbB signalling may also contribute to prostate cancer
metastatsis as we have found expression of these genes in
CTC isolated from the peripheral blood of AIPC patients,
gefitinib treatment has been reported to inhibit EGF
induced invasion of prostate cancer cells [29] and Hedge-
hog signalling has also been linked to metastasis [11,12].
Combination chemotherapy targeting these signalling
pathways therefore also has the potential to be beneficial
in metastatic prostate cancer.
Our findings are consistent with Hedgehog and ErbB
being of therapeutic relevance to the management of pros-
tate cancer. Hedgehog signalling may be an important
new target in metastatic AIPC. Although, at present, there
is no clinically available treatment that specifically targets
the Hedgehog signalling pathway. The SMO inhibitor
cyclopamine, which we show can be used to inhibit AIPC
cell proliferation, along with other Hedgehog signalling
targeting compounds are currently being developed
(Curis, USA) and a Phase I clinical trial of a systemically
administered small molecule Hedgehog antagonist initi-
ated (Genentech, USA). In addition, as significant clinical
improvements have not been reported using ErbB signal-
ling inhibitors alone (Herceptin or Gefitinib) in phase II
clinical trials for advanced prostate cancer [10,30]. Com-
bination therapy targeting both Hedgehog and ErbB sig-
nalling may enable enhanced anticancer efficacy with no
greater toxicity, thus improving the treatment of advanced
prostate cancer.
Conclusion
Our results suggest that the Hedgehog and ErbB signalling
may play an important role in the proliferation of andro-
gen-independent prostate cancer cells. As we observed
expression of PTCH, GLI1, EGFR and ErbB2 in AIPC cells
and that inhibitors of these signalling pathways in combi-
nation had synergistic anti-proliferative effects. The
Hedgehog pathway therefore represents a potential new
therapeutic target in advanced prostate cancer and combi-
nation therapy against Hedgehog and ErbB pathways
could also be considered.
Methods
Cell and tissue culture
Androgen-dependent LNCaP cells were obtained from the
American Type Culture Collection (ATCC). Androgen-
independent LNCaP C4-2B cells were purchased from
Viromed Laboratories. Cells were grown at 37°C in RPMI
media without phenol red (Sigma) supplemented with
10% (v/v) fetal bovine serum (Invitrogen) or 10% (v/v)
charcoal stripped FBS (Hyclone), 2.4 mM glutamine
Table 1: Dose-effect relationships of drug combinations in human androgen-independent prostate cancer cell line LNCaP C4-2B: 
Gefitinib (Ge), Lapatinib (La) and Cyclopamine (Cy).
Treatment Parameters CI value at Range Significance
Dm mr E D 50 ED75 ED90
Ge+Cy (12:1) 9.5 0.44 0.94 0.22 0.06 0.02 0.1–0.3 strong synergism
La+Cy (7:1) 5.8 0.44 0.94 0.14 0.06 0.03 0.1–0.3 strong synergismCancer Cell International 2008, 8:3 http://www.cancerci.com/content/8/1/3
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(Sigma), 1% (v/v) pyruvate (Sigma), penicillin and strep-
tomycin (50 U and 50 µg/ml) (Invitrogen). Cells were
treated with EGF (Sigma), cyclopamine (Sigma), gefitinib
(AstraZenica) and lapatinib (Glaxo-Smithkline) as
detailed.
Isolation of circulating tumour cells
Peripheral blood samples were obtained from 15 patients
(anonymised for confidentiality according to the format
ABC 12) and 5 normal male subjects (named NORM 1–5,
all under 40 years of age with no significant intercurrent
illness). Two 10 ml peripheral blood samples were col-
lected in EDTA coated tubes (Greiner), kept on ice and
processed within three hours of collection. Samples were
processed through Oncoquick (Greiner) tubes, as per the
manufacturer's instructions. In order to further purify the
CTC the Oncoquick enriched samples were depleted of
CD45 positive cells and positively selected for EpCAM
expressing cells using AutoMACS™ (Miltenyi biotech).
The study was fully approved by the Local Research Ethics
Committee (reference number 05/Q0602/48).
Analysis of cyclopamine and (A-B) gefitinib or (C-D) lapatinib in LNCaP C4-2B cells Figure 6
Analysis of cyclopamine and (A-B) gefitinib or (C-D) lapatinib in LNCaP C4-2B cells. (A and C) combination index 
plot for the drug combinations. (B and D) Isobologram for the combination of gefitinib or (C-D) lapatinib and cyclopamine for 
effect level (Fa = 0.5). Note the combination data points fall on the lower left of the hypotenuse for Fa = 0.5 (shown), Fa = 0.75 
and Fa = 0.9 indicating synergism.Cancer Cell International 2008, 8:3 http://www.cancerci.com/content/8/1/3
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RNA isolation, amplification, reverse transcription and 
quantitative PCR
RNA was isolated from the samples using the RNeasy Mini
kit (Qiagen). cDNA was synthesized following DNAse
treatment by reverse transcription using Superscript III
(Invitrogen) with oligo-dT priming. QPCR was performed
using Platinum SYBR®Green qPCR Supermix-UDG (Invit-
rogen) using the Opticon DNA Engine 2™. Primers used
are detailed in Table 2. The relative expression of β2-
microglobulin was used as an internal control.
Antibodies and immunoblotting
Primary antibodies used were as follows: EGFR (#2232
Cell Signalling); Phospho-EGFR (#2231 Cell Signalling);
Phospho-ErbB2 (#2241 Cell Signalling); Patched (#sc-
6149 Santa Cruz Biotechnology); EpCAM (#ab20160
Abcam) and GAPDH (# ab9485 Abcam). For immunoflu-
oresence staining CTCs were air dried onto slides, fixed
with methanol and incubated with primary antibodies
(1:400 phospho-EGFR; 1:250 Phospho-ErbB2; 1:250
EpCAM; 1:200 Patched) overnight in blocking buffer and
detected using appropriate secondary antibodies. Nuclear
counterstaining was performed using DAPI. Stained prep-
arations were analysed on a Zeiss 510 confocal micro-
scope. For western blotting cultured cells at 70–80%
confluence were washed twice with PBS and lysed in RIPA
buffer containing Sigma Phosphatase Inhibitor Cocktails
I & II and Roche Protease Inhibitor Complete EDTA-free.
Lysates were cleared by centrifugation at 16,000 × g for 10
mins. 20 ug of each lysate was boiled for 10 mins in Inv-
itrogen sample buffer with antioxidant and resolved using
the Invitrogen NuPage system on a 10% Bis-Tris gel with
MOPS buffer, then transferred to Amersham Hybond-C
extra membrane. The membranes were blocked for 30
mins in 5% milk or 5% BSA (GAPDH) in TBS-T. Primary
antibodies (1:1000 pEGFR and pEGFR; 1:5000 GAPDH)
were incubated overnight at 4°C with blocking and visu-
alised using an appropriate HRP-conjugated secondary
antibody using enhanced chemiluminescence (ECL,
Amersham).
MTT assay for cell proliferation
The MTT [3-(4,5-dimethylthiazol-2-yl)-2, 5-diphe-
nyltetrazolium bromide] assay is based on the ability of a
mitochondrial dehydrogenase enzyme from viable cells to
cleave the tetrazolium rings of the pale yellow MTT and
form dark blue formazan crystals which are largely imper-
meable to cell membranes, thus resulting in its accumula-
tion within viable cells. The colour can then be quantified
using a simple colorimetric assay. Cells were seeded onto
96 well plates at 2–4 × 104/well in 200 µl media and syn-
chronized in G0 (quiescent) phase of the growth cycle by
culture in serum free medium. After 12 hours this serum
free medium was replaced with 10% Fetal Bovine Serum
in RPMI containing inhibitors as detailed. After 48 hours
20 µl of the 5 mg/ml MTT substrate was added to each
well. Plates were returned to the incubator and left in the
dark for 1 hour. After the incubation period, MTT sub-
strate/medium was gently removed from each well and
200 µl of DMSO were added to each well to dissolve the
MTT formazan crystals and absorbance measured spectro-
photometrically at a wavelength of 570 nm. Blank control
Table 2: Oligonucleotides used for PCR amplification
Gene Sequence 5'-3' Size of product (Base Pairs)
AR-f GACGCTTCTACCAGCTCACC 60
AR-r GAAAGGATCTTGGGCACTTG
β-actin-f GATGAGATTGGCATGGCTTT 60
β-actin-r CACCTTCACCGTTCCAGTTT
DD3PCA3 GGTGGGAAGGACCTGATGATAG 58
DD3PCA3 GGGCGAGGCTCATCGAT
ErbB2-f CCTCTGACGTCCATCGTCTC 100
ErbB2-r CGGATCTTCTGCTGCCGTCG
EGFR-f CTTCTTGCAGCGATACAGCTC 439
EGFR-r ATGCTCCAATAAATTCACTGC
GLI1-f GAAGACCTCTCCAGCTTGGA 306
GLI1-r GGCTGACAGTATAGGCAGAG
GREX-f* GAGTACCTCTGGAGGACAGA 281
GRINTRON-r* ATGTCCATTCTTAAGAAACAGGA
PSA-f GGTGACCAAGTTCATGCTGTG 194
PSA-r GTGTCCTTGATCCACTTCCG
PTCH-1-f CTCCCAAGCAAATGTACGAGCA 150
PTCH-1-r TGAGTGGAGTTCTGTGCGACAC
β2-microglobulin-f TGAATTCGTATGTGTCTGGGT 247
β2-microglobulin-r CCTCCATGATGCTGCTTACAT
* GREX/GRINTRON = glucocorticoid receptor intron genomic DNA control. Sequence for GRINTRON crosses boundary of glucocorticoid 
receptor gene intron and exon. No product is formed unless genomic DNA is present.Cancer Cell International 2008, 8:3 http://www.cancerci.com/content/8/1/3
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values were then subtracted from the 570 nm values and
relative growth rates were calculated. All experiments car-
ried out using MTT assay were carried out on three sepa-
rate occasions.
Determination of IC50 concentration for cytotoxic drugs
Androgen-independent LNCaP C4-2B cells growing in
androgen free medium were harvested by trypsinisation,
washed and seeded at 30,000 per well in 96 well plates
and left to attach overnight. The IC50 doses were deter-
mined by exposing cells to various concentrations of the
drugs 10-7–10-3M for 72 hours. The medium with drug
was aspirated and the MTT assay described above was per-
formed. The IC50 was defined as the concentration of drug
at which there was a 50% less growth when compared to
control cells. Each experiment was performed in triplicate.
Median effect analysis
The isobologram and combination index (CI) were calcu-
lated according to the Chou and Talalay median effect
principal [24] using Calcusyn software (Biosoft). The
drugs were applied at a fixed ratio of the IC50 across a
range of activities and viability was evaluated using the
MTT assay at each dosage. Data from cell viability assay
were expressed as the fraction of cells inhibited by drug
treatments compared with untreated cells. Interaction
between pairs of drugs was determined using the Calcusyn
computed isolobogram and combination index (CI). The
isobologram is a graphical representation of the interac-
tion between two drugs and is formed by plotting the
individual drug doses required to achieve a single agent
effect on their respective x and y axes, a line connecting the
two points is drawn and the concentrations of the two
drugs used in combination to achieve the same effect are
plotted on the isobologram. Combination data points
that fall on the line represent an additive interaction,
whereas points above or below represent antagonism or
synergy respectively. The CI analysis is similar to the iso-
bologram provides qualitative information on the drug
interaction and a numerical CI value is calculated based
on the following equation: CI = (D)1/(Dx)1 + (D)2/
(Dx)2 + (D)1(D)2/(Dx)1(Dx)2, where (D)1 and (D)2 are
the doses of drug 1 and drug 2 that have x% effect when
used in combination, and (Dx)1 and (Dx)2 are the doses
of drug 1 and drug 2 that have the same x% effect when
used alone. The CI indicates synergism when <0.9, antag-
onism when >1.1 and additivity when 0.9–1.1. The Cal-
cusyn software also calculates the median effect dose (Dm)
of each combination, shape of the dose-effect curve (m)
and linear correlation coefficient of the median effect plot
(r) indicating conformity of date.
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